{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:25Z","timestamp":1786980385782,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00702-026-03161-9","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:12:15Z","timestamp":1776787935000},"page":"1481-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson\u2019s disease"],"prefix":"10.1007","volume":"133","author":[{"given":"Daiki","family":"Kamiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"3161_CR1","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin M, Martinelli P (2010) Pharmacokinetics of levodopa. J Neurol 257:S253\u2013261. https:\/\/doi.org\/10.1007\/s00415-010-5728-8","journal-title":"J Neurol"},{"key":"3161_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2022-329849","volume":"95","author":"C Kramarz","year":"2023","unstructured":"Kramarz C, Murphy E, Reilly MM, Rossor AM (2023) Nutritional peripheral neuropathies. J Neurol Neurosurg Psychiatry 95:61\u201372. https:\/\/doi.org\/10.1136\/jnnp-2022-329849","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3161_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1600-0773.1990.tb00756.x","volume":"66","author":"PT Mannisto","year":"1990","unstructured":"Mannisto PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson\u2019s disease. Pharmacol Toxicol 66:317\u2013323. https:\/\/doi.org\/10.1111\/j.1600-0773.1990.tb00756.x","journal-title":"Pharmacol Toxicol"},{"key":"3161_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0165-6147(89)90075-8","volume":"10","author":"PT Mannisto","year":"1989","unstructured":"Mannisto PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson\u2019s disease? Trends Pharmacol Sci 10:54\u201356. https:\/\/doi.org\/10.1016\/0165-6147(89)90075-8","journal-title":"Trends Pharmacol Sci"},{"key":"3161_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/cphy.c150021","volume":"6","author":"KS McCully","year":"2015","unstructured":"McCully KS (2015) Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol 6:471\u2013505. https:\/\/doi.org\/10.1002\/cphy.c150021","journal-title":"Compr Physiol"},{"key":"3161_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00702-023-02666-x","volume":"131","author":"T Muller","year":"2024","unstructured":"Muller T, Riederer P (2024) The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson\u2019s disease. J Neural Transm (Vienna) 131:631\u2013638. https:\/\/doi.org\/10.1007\/s00702-023-02666-x","journal-title":"J Neural Transm (Vienna)"},{"key":"3161_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","volume":"75","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T (2015) Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs 75:157\u2013174. https:\/\/doi.org\/10.1007\/s40265-014-0343-0","journal-title":"Drugs"},{"key":"3161_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archneur.61.5.633","volume":"61","author":"P O'Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain P, Diaz-Arrastia R (2004) Levodopa elevates homocysteine: is this a problem? Arch Neurol 61:633\u2013634. https:\/\/doi.org\/10.1001\/archneur.61.5.633","journal-title":"Arch Neurol"},{"key":"3161_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archneur.61.6.865","volume":"61","author":"PE O\u2019Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain PE, Hernandez SV, Lacritz C, Dewey L, Bottiglieri RB Jr, Diaz-Arrastia T (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61:865\u2013868","journal-title":"Arch Neurol"},{"key":"3161_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/mds.20243","volume":"19","author":"CW Olanow","year":"2004","unstructured":"Olanow CW et al (2004) Levodopa in the treatment of Parkinson\u2019s disease: current controversies. Mov Disord 19:997\u20131005. https:\/\/doi.org\/10.1002\/mds.20243","journal-title":"Mov Disord"},{"key":"3161_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/mds.27216","volume":"33","author":"CW Olanow","year":"2018","unstructured":"Olanow CW, Stocchi F (2018) Levodopa: a new look at an old friend. Mov Disord 33:859\u2013866. https:\/\/doi.org\/10.1002\/mds.27216","journal-title":"Mov Disord"},{"key":"3161_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00702-023-02684-9","volume":"130","author":"O Phokaewvarangkul","year":"2023","unstructured":"Phokaewvarangkul O et al (2023) Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson\u2019s disease: clinical and therapeutic considerations. J Neural Transm (Vienna) 130:1451\u20131462. https:\/\/doi.org\/10.1007\/s00702-023-02684-9","journal-title":"J Neural Transm (Vienna)"},{"key":"3161_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"3161_CR14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"3161_CR15","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","volume":"66","author":"RB Postuma","year":"2006","unstructured":"Postuma RB, Zadikoff AJEC, Suchowersky O, Martin WRW, Lafontaine A-L, Ranawaya R, Camicioli R, Lang AE (2006) Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66:1941\u20131943","journal-title":"Neurology"},{"key":"3161_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1373\/clinchem.2003.021634","volume":"50","author":"H Refsum","year":"2004","unstructured":"Refsum H et al (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50:3\u201332. https:\/\/doi.org\/10.1373\/clinchem.2003.021634","journal-title":"Clin Chem"},{"key":"3161_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/s1474-4422(06)70508-7","volume":"5","author":"C Warren Olanow","year":"2006","unstructured":"Warren Olanow C, Stocchi JAOF (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5:677\u2013687. https:\/\/doi.org\/10.1016\/s1474-4422(06)70508-7","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03161-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:06:35Z","timestamp":1785600395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03161-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3161"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03161-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Kamiyama, Iwaki, Abe, Ueno, Shiina and Noda declare no conflicts of interest. Dr. Nishikawa has received grants from the Japan Society for the Promotion of Science (JSPS-KAKENHI; Grant Number: 24K09947). She has received honoraria for lectures from Ono Pharmaceutical Co., Ltd., AbbVie GK, and Teijin Pharma Limited. She has also received advisory fees and funding for investigator-initiated clinical research from AbbVie GK, outside the submitted work. Dr. Hatano has received grants from the Japan Agency for Medical Research and Development: AMED (No: 24dk0207072, 24wm0425015, 24bm1423015, 24dk0207055, 24wm0425019, 24wm0625503), the Japan Society for the Promotion of Science: JSPS-Kakenhi (No: 24K02373), and honoraria for lectures from Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Eisai Co. Ltd., Kowa Company, Ltd., EA Pharma Co., Ltd. and Elli Lilly Japan KKd.Dr. Hattori has received grants from the Japan Agency for Medical Research and , Development: AMED (No: 24ak0101236, 24ek0109677, 24bm1423015, 24wm0625503), the Japan Society for the Promotion of Science: JSPS-Kakenhi (No: 24H00068, 23K20044), JST (Moonshot R&D Program) grant No. JPMJMS2024, Grant No. JPMH23FC1008 by Ministry of Health, Labour and Welfare Japan, and honoraria for lectures or consulting fees from Sumitomo Pharma Co. Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Eisai Co. Ltd., Biogen Idec Japan Ltd., AbbVie GK, Teijin Pharma Ltd, Alexion Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., PARKINSON Laboratories, Co., Ltd, MEDICOLAB and Yoda Therapeutics, Inc., outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}